Jean is a General Partner of Advanced Technology Ventures (ATV) and focuses on investments in the biopharmaceutical and medical device sectors. She is based in the firm’s Boston office, where she also serves as a General Partner for Lightstone Ventures. Her representative investments include Acceleron Pharma, Calithera Biosciences, Five Prime Therapeutics, Hydra Biosciences, Hypnion (acquired by Eli Lilly), Portola Pharmaceuticals (NASDAQ: PTLA), Proteolix (acquired by Onyx Pharmaceuticals), Thrasos Therapeutics, Verastem (NASDAQ: VSTM), and Zeltiq Aesthetics (NASDAQ: ZLTQ).
Jean has been featured on the Forbes Midas List and was previously a member of the Scientific Advisory Board for the Massachusetts Life Sciences Center. She has been in the biopharmaceutical industry for over 20 years, including 10 years with Genzyme Corporation, where she held a variety of operational roles in marketing, product development, and business development, including Vice President of Global Sales and Marketing. She also was Vice President and Founder of Genzyme's Tissue Repair Division, where she was responsible for identifying new product opportunities and potential acquisition candidates.
Prior to ATV, Jean led life science investments for BancBoston Ventures where her investments included Neurometrix (NASDAQ: NURU), Ironwood Pharmaceuticals (NASDAQ: IRWD), NuGenesis Technologies (acquired by Waters), and Syntonix Pharmaceuticals (acquired by Biogen/Idec). Previously, Jean spent six years working in chemistry and bioresearch.
Jean earned an M.B.A. from Simmons College Graduate School of Management and a B.S. from the University of Maine.
Five Prime Therapeutics
Hypnion (acquired by Eli Lilly)
Portola Pharmaceuticals (NASDAQ: PLTA)
Proteolix (acquired by Onyx Pharmaceuticals)
Verastem (NASDQ: VSTM)
Zeltiq Aesthetics (NASDAQ: ZLTQ)